13 Buys, zero Sells, ₹537 target — and one cash-flow number nobody is pricing.

• The consensus is one-sided. 13 of 13 sell-side analysts rate Buy or Strong Buy with a median 12-month target of ₹537 (~52% upside). The pitch: pre-sales +25% YoY, IND AA Stable rating, net D/E of 0.06x, and a 1.42x P/B that screens cheap vs Lodha at 3.79x and Oberoi at 3.72x.
• The gap is twelve years deep. Cumulative audited operating cash flow FY15–FY26 totals ₹148cr against ₹1,355cr of cumulative net income — a 0.11× conversion. FY26 alone swung to negative ₹432cr CFO while management headlined a ₹552cr 'Net Operating Cash Flow Surplus' — a ₹984cr divergence in a single year, with no published reconciliation.
• The ₹537 target implicitly assumes the lag reverses. Consensus FY27 EPS of ~₹22 requires the 0.11× conversion to normalise as the ₹5,528cr customer-advance reservoir converts to handover revenue. If H1 FY27 audited CFO prints negative again, 13 brokers cut DCFs and NAVs simultaneously.

The P&L finally caught up with pre-sales — the cash statement went the other way.

Indian RE recognises revenue at handover, so reported revenue lags pre-sales by 2–4 years — true. But cumulative audited CFO of ₹148cr against ₹1,355cr of net income across twelve years is not lag; it is a structural feature of an inventory pile (₹6,206cr, 75% of total assets) that has never settled to bank cash. FY26's ₹-432cr operating outflow was plugged by ₹538cr of new financing — preferential warrants, secured debt, an HDFC Bank facility. The reservoir of ₹5,528cr in customer advances is 1.5× book equity and contractually real; whether it actually arrives as cash on a 3-year clip is the FY27–FY28 test.

The founder owns more than half the company — and skipped every audit committee meeting in FY25.

• Skin is real. Kamal Khetan founded the business in 2000, owns 55.65% directly (~₹2,877cr at today's price, ~710× his annual cash pay), and has zero pledged shares. FII holding climbed to 20.58% in March 2026 even as the stock fell 18% YTD; foreign sponsorship is building.
• The empty chair. Per the FY25 Corporate Governance Report, the CMD attended 0 of 6 audit committee meetings despite being a member. His ₹4.05cr pay is 100% fixed cash — no bonus, no ESOPs, no performance hurdle — directly in tension with the company's own remuneration policy that calls for 'balance between fixed and incentive pay'.
• The offshore loan book. Related-party loans grew 78% YoY to ₹361cr in FY25, with the Sunteck Lifestyles International JLT line (Mauritius/UAE conduit for the Dubai launch) jumping from ₹0.66cr to ₹80cr in one year. Dubai is now indefinitely stalled by Middle East unrest. Auditor Walker Chandiok was flagged by NFRA in December 2023 for firm-wide quality-control deficiencies.

Two prints — early August and late October 2026 — will decide the trade.

• Q1 FY27 audited CFO (~5–8 Aug 2026). First public test of Khetan's 'FY27 and FY28 will be very, very strong cash flow' claim. ≥₹150cr CFO with collections crossing 50% of pre-sales = the cycle-artefact framing wins. A second consecutive ₹200cr+ outflow lands the bear's primary trigger directly.
• Nepean Sea Road RERA + first sales (by end-Sep 2026). Project has slipped 4+ quarters from a Q4 FY25 guide; the chairman pushed back hard on the Q3 FY26 call — 'it's not dragged at all' — the most defensive moment in 12 transcripts. RERA in hand plus invitation-only 'Emaance' sales above ₹2 lakh/sq ft = bull primary catalyst lands.
• Goldman / Morgan Stanley follow-through. GS+MS acquired 4.9% from CLSA on 29-Jan-2026 at ₹375 (₹268cr); a 23.6 million-share / 33× ADV block printed on 22-Apr. The Sep-2026 FII shareholding pattern (visible early October) tells you whether smart money is building or whether CLSA was just exiting at a 50% drawdown low.